• DOI:10.2217/pgs-2018-0138
Corpus ID: 58610607

Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.

@article{Wei2019CosteffectivenessAO,
  title={Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.},
  author={Xiaoxia Wei and Jiaqin Cai and H. Sun and N. Li and Chenxia Xu and G. Zhang and Yuxia Sui and J. Zhuang and B. Zheng},
  journal={Pharmacogenomics},
  year={2019},
  volume={20 4},
  pages={
          241-249
        }
}

Xiaoxia Wei, Jiaqin Cai, +6 authors B. Zheng

Published 2019

Medicine

Pharmacogenomics

AIM To assess the cost-effectiveness of UGT1A1*6/*28 genotyping compared with no genotyping or no dose adjustment before irinotecan administration in China. MATERIALS & METHODS A decision tree model was developed to evaluate costs and health outcomes represented as quality-adjusted life years gained. Model inputs for the frequency of genotypes, the probability of neutropenia under FOLFIRI chemotherapy and direct costs and utilities were obtained from published sources. One-way sensitivity… CONTINUE READING

View on PubMed

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed